Takahashi, T.; Saito, A.; Yorozuya, T.; Nishikiori, H.; Kuronuma, K.; Chiba, H.
Exploring the Potential of a P2X3 Receptor Antagonist: Gefapixant in the Management of Persistent Cough Associated with Interstitial Lung Disease. Medicina 2025, 61, 892.
https://doi.org/10.3390/medicina61050892
AMA Style
Takahashi T, Saito A, Yorozuya T, Nishikiori H, Kuronuma K, Chiba H.
Exploring the Potential of a P2X3 Receptor Antagonist: Gefapixant in the Management of Persistent Cough Associated with Interstitial Lung Disease. Medicina. 2025; 61(5):892.
https://doi.org/10.3390/medicina61050892
Chicago/Turabian Style
Takahashi, Tomoyuki, Atsushi Saito, Takafumi Yorozuya, Hirotaka Nishikiori, Koji Kuronuma, and Hirofumi Chiba.
2025. "Exploring the Potential of a P2X3 Receptor Antagonist: Gefapixant in the Management of Persistent Cough Associated with Interstitial Lung Disease" Medicina 61, no. 5: 892.
https://doi.org/10.3390/medicina61050892
APA Style
Takahashi, T., Saito, A., Yorozuya, T., Nishikiori, H., Kuronuma, K., & Chiba, H.
(2025). Exploring the Potential of a P2X3 Receptor Antagonist: Gefapixant in the Management of Persistent Cough Associated with Interstitial Lung Disease. Medicina, 61(5), 892.
https://doi.org/10.3390/medicina61050892